FindTrial
Sign In

Gallium Ga 68-labeled PSMA-11

DRUG9 trials

Sponsors

University of California, San Francisco, Jonsson Comprehensive Cancer Center, City of Hope Medical Center, M.D. Anderson Cancer Center

Conditions

Biochemically Recurrent Prostate CarcinomaBreast CarcinomaColon CarcinomaEsophageal CarcinomaGastric CarcinomaHead and Neck CarcinomaKidney CarcinomaLung Carcinoma

Early Phase 1

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Active, not recruitingNCT04147494
Jonsson Comprehensive Cancer CenterBreast Carcinoma, Colon Carcinoma, Esophageal Carcinoma +8
Start: 2019-11-05End: 2031-10-17Updated: 2025-08-12
Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
CompletedNCT04282824
Jonsson Comprehensive Cancer CenterProstate Carcinoma
Start: 2019-06-05End: 2020-05-06Updated: 2020-12-02

Phase 1

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
CompletedNCT04216134
City of Hope Medical CenterBiochemically Recurrent Prostate Carcinoma
Start: 2019-12-12End: 2022-12-09Updated: 2023-06-15

Phase 2

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
TerminatedNCT03463889
University of California, San FranciscoThyroid Gland Carcinoma
Start: 2018-03-19End: 2020-10-31Updated: 2021-06-29
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
CompletedNCT03515577
Jonsson Comprehensive Cancer CenterRecurrent Prostate Carcinoma
Start: 2019-04-12End: 2019-04-25Updated: 2020-10-14
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
CompletedNCT04050215
Jonsson Comprehensive Cancer CenterBiochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma +6
Start: 2018-04-02End: 2021-09-27Updated: 2021-09-30
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
WithdrawnNCT05034562
M.D. Anderson Cancer CenterMetastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IVA Prostate Cancer AJCC v8 +2
Start: 2022-09-26End: 2022-09-26Updated: 2024-03-07

Phase 3

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
Active, not recruitingNCT03582774
Jonsson Comprehensive Cancer CenterRecurrent Prostate Carcinoma
Start: 2018-07-12End: 2027-07-12Target: 193Updated: 2025-05-13

Unknown Phase

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
CompletedNCT03857087
University of California, San FranciscoOvarian Carcinoma
Start: 2018-04-02End: 2022-06-30Updated: 2022-10-12

Related Papers

FAP Expression in Renal Tumors Assessed by [<sup>68</sup>Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494.
2026-01-02
PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.
Journal of Clinical Oncology2023-06-0113 citations
Incidental Focal<sup>68</sup>Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion
Journal of Nuclear Medicine2022-12-295 citations
Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management: Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774].
Journal of Clinical Oncology2022-06-012 citations
PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial
BMC Cancer2022-03-0820 citations
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
PubMed2022-02-019 citations
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
Journal of Nuclear Medicine2021-10-0730 citations
Abstract LB038: Validation of FAPi PET biodistribution by immunohistochemistry in patients with solid cancers: a prospective exploratory study
Cancer Research2021-07-01
Validation of FAPi PET biodistribution by immunohistochemistry in patients with solid cancers: A prospective exploratory study.
Journal of Clinical Oncology2021-05-204 citations
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
2021-05-0718 citations
Impact of PSMA PET/CT on SRT planning: Preliminary results from the randomized phase III trial NCT03582774.
Journal of Clinical Oncology2021-02-204 citations
Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer
Clinical Nuclear Medicine2020-07-2217 citations
Comparison of recurrence patterns after surgery and radiation therapy with 68Ga-PSMA-11 PET/CT in nonmetastatic castrate-sensitive prostate cancer patients: A single-center post-hoc retrospective analysis in 787 patients.
Journal of Clinical Oncology2020-05-20
Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings.
Journal of Clinical Oncology2020-02-19
Total-Body <sup>68</sup>Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
Journal of Nuclear Medicine2019-09-2047 citations
Randomized prospective phase 3 trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
Journal of Clinical Oncology2019-05-2024 citations
Prospective head-to-head comparative phase 3 study between <sup>18</sup>F-fluciclovine and <sup>68</sup>Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.
Journal of Clinical Oncology2019-05-20
Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.
Journal of Clinical Oncology2019-03-0113 citations
Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
Journal of Clinical Oncology2019-03-016 citations
Randomized prospective phase III trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
2019-01-0776 citations